Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07539883

Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study

This study aims to evaluate the clinical effectiveness of the oXiris® hemofilter in patients with septic shock and acute kidney injury (AKI) requiring continuous renal replacement therapy (CRRT). While some studies suggest that oXiris® may improve hemodynamic stability by removing endotoxins and cytokines, its impact on survival remains inconsistent.To provide more reliable causal evidence, this multicenter retrospective cohort study utilizes a Target Trial Emulation (TTE) approach. The study will compare patients treated with the oXiris® filter to those treated with standard CRRT filters, focusing on in-hospital mortality and other clinical outcomes such as fluid balance and vasopressor requirements.

Recruiting

Interested in participating?

Request Info

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea

Location status: Recruiting

Location contact

Myung Jin Song, MD.PhD

CONTACT

[email protected]

82+1045990531

Sung Yoon Lim, MD PhD

CONTACT

[email protected]

82+1028469179

About this study

Background:

Septic shock is characterized by a dysregulated host response to infection, leading to a "cytokine storm" that causes organ dysfunction and hemodynamic instability. Extracorporeal blood purification (EBP) using the oXiris® filter is designed to restore immune homeostasis by adsorbing both endotoxins and cytokines while performing standard CRRT functions. However, existing observational data often suffer from selection and immortal time biases.

Study Design and Methodology:

This study employs the Target Trial Emulation (TTE) framework to mimic the design of a randomized controlled trial using retrospective observational data.

  • Target Population: Adult patients (≥19 years) admitted to the ICU with septic shock and AKI requiring CRRT between March 2021 and August 2025.
  • Time Zero: Defined as the initiation of CRRT.
  • Treatment Strategies:

Strategy A (oXiris): CRRT initiated with the oXiris® filter. Strategy B (Control): CRRT initiated with a standard filter, sourced from the Korea Sepsis Alliance registry.

  • Data Sources: Data will be collected from five major medical centers in South Korea: Seoul National University Bundang Hospital, Hallym University Sacred Heart Hospital, Chung-Ang University Hospital, Samsung Medical Center, and Asan Medical Center.
  • Statistical Analysis Plan:

To adjust for baseline confounding and confounding by indication, propensity score-based Inverse Probability of Treatment Weighting (IPTW) will be applied.

Primary Outcome: In-hospital mortality will be analyzed using an IPTW-weighted Cox proportional hazards model.

Secondary Outcomes:

  • Fluid Balance: 3-day cumulative fluid balance using landmark analysis and IPTW-weighted linear regression.
  • Vasopressor Weaning: Analyzed using a weighted Fine-Gray risk model, considering death as a competing risk.
  • Organ Function & Inflammation: Repeated measures of SOFA scores and inflammatory markers (CRP, Procalcitonin, lactate) using IPTW-weighted linear mixed-effects models.
  • Renal Recovery: Evaluated via IPTW-weighted logistic regression.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 19 years or older.
  • Admitted to the ICU with septic shock (Sepsis-3 criteria) between March 2021 and August 2025.
  • Required Continuous Renal Replacement Therapy (CRRT) due to acute kidney injury (AKI).

Exclusion criteria

  • Death or withdrawal of life-sustaining therapy within 48 hours of ICU admission.
  • Patients with End-Stage Renal Disease (ESRD).
  • Patients with missing critical covariates.

Treatment and study plan

Primary outcomes

  1. In-hospital Mortality

    Time frame: From the initiation of CRRT (Time zero) until hospital discharge or death.

    The primary objective is to evaluate the causal effect of oXiris® hemofilter use on survival during the hospital stay compared to standard CRRT. Statistical analysis will be performed using an Inverse Probability of Treatment Weighting (IPTW)-weighted Cox proportional hazards model to adjust for baseline and time-varying confounders.

Secondary outcomes

  1. 3-day Cumulative Fluid Balance

    Time frame: 3 days after CRRT initiation.

    Comparison of the total fluid intake and output over the first 3 days after CRRT initiation.

  2. Time to Vasopressor Weaning

    Time frame: From CRRT initiation through ICU discharge, up to 28 days

    The duration from CRRT initiation until the successful discontinuation of all vasopressors.

  3. Organ Dysfunction Improvement

    Time frame: Baseline (Day 0) and Days 1, 2, 3, 7 of ICU stay.

    Evaluation of organ failure improvement through repeated measures of the Sequential Organ Failure Assessment (SOFA) score.

  4. Changes in Inflammatory Markers

    Time frame: Baseline (Day 0) and Days 1, 2, 3, 7 of ICU stay.

    Assessment of the reduction in serum levels of CRP, Procalcitonin, and lactate.

  5. Renal Recovery Status

    Time frame: From CRRT initiation through hospital discharge, up to 90 days

    Proportion of patients who recover renal function and do not require renal replacement therapy at the time of hospital discharge.

Study contacts

Contact information is provided by the study sponsor or research team.

Myung Jin Song, MD.PhD

CONTACT

[email protected]

82+1045990531

Sung Yoon Lim, MD. PhD

CONTACT

[email protected]

82+1028469179

Sponsors and collaborators

Lead sponsor

Seoul National University Bundang Hospital

Other

Collaborators

  • Vantive Health LLC

Registry information

Official study title

Official Title: Effect of oXiris Hemofilter Use in Septic Shock: A Multicenter Retrospective Cohort Study Using a Target Trial Emulation Approach

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Apr 20, 2026
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.